Диссертация (1140781), страница 18
Текст из файла (страница 18)
B., Prystowsky E. N.,Tamargo J. L., Wann S., Smith S. C., Jacobs A. K., Adams C. D., Anderson J. L., Antman118E. M., Hunt S. A., Nishimura R., Ornato J. P., Page R. L., Riegel B., Priori S. G., BlancJ. J., Budaj A., Camm A. J., Dean V., Deckers J. W., Despres C., Dickstein K., LekakisJ., McGregor K., Metra M., Morais J., Osterspey A., Zamorano J. L., Guidelines A. C. o.C. A. H. A. T. F. o. P., Guidelines E. S. o. C. C. f.
P., Association E. H. R., Society H. R.ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation:a report of the American College of Cardiology/American Heart Association Task Forceon Practice Guidelines and the European Society of Cardiology Committee for PracticeGuidelines (Writing Committee to Revise the 2001 Guidelines for the Management ofPatients With Atrial Fibrillation): developed in collaboration with the European HeartRhythm Association and the Heart Rhythm Society // Circulation.
‒ 2006. ‒ T. 114, № 7.‒ C. e257-354.68. Giugliano R. P., Ruff C. T., Braunwald E., Murphy S. A., Wiviott S. D., Halperin J.L., Waldo A. L., Ezekowitz M. D., Weitz J. I., Špinar J., Ruzyllo W., Ruda M., KoretsuneY., Betcher J., Shi M., Grip L. T., Patel S. P., Patel I., Hanyok J. J., Mercuri M., AntmanE.
M., Investigators E. A.-T. Edoxaban versus warfarin in patients with atrial fibrillation// N Engl J Med. ‒ 2013. ‒ T. 369, № 22. ‒ C. 2093-104.69. Gladstone D. J., Spring M., Dorian P., Panzov V., Thorpe K. E., Hall J., Vaid H.,O'Donnell M., Laupacis A., Côté R., Sharma M., Blakely J. A., Shuaib A., Hachinski V.,Coutts S. B., Sahlas D. J., Teal P., Yip S., Spence J. D., Buck B., Verreault S., CasaubonL. K., Penn A., Selchen D., Jin A., Howse D., Mehdiratta M., Boyle K., Aviv R., KapralM.
K., Mamdani M., Coordinators E. I. a. Atrial fibrillation in patients with cryptogenicstroke // N Engl J Med. ‒ 2014. ‒ T. 370, № 26. ‒ C. 2467-77.70. Go A. S., Fang M. C., Udaltsova N., Chang Y., Pomernacki N. K., Borowsky L.,Singer D. E., Investigators A. S. Impact of proteinuria and glomerular filtration rate onrisk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrialfibrillation (ATRIA) study // Circulation. ‒ 2009.
‒ T. 119, № 10. ‒ C. 1363-9.71. Go A. S., Hylek E. M., Phillips K. A., Chang Y., Henault L. E., Selby J. V., SingerD. E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm119management and stroke prevention: the AnTicoagulation and Risk Factors in AtrialFibrillation (ATRIA) Study // JAMA. ‒ 2001. ‒ T. 285, № 18.
‒ C. 2370-5.72. Granger C. B., Alexander J. H., McMurray J. J., Lopes R. D., Hylek E. M., HannaM., Al-Khalidi H. R., Ansell J., Atar D., Avezum A., Bahit M. C., Diaz R., Easton J. D.,Ezekowitz J. A., Flaker G., Garcia D., Geraldes M., Gersh B. J., Golitsyn S., Goto S.,Hermosillo A. G., Hohnloser S. H., Horowitz J., Mohan P., Jansky P., Lewis B.
S., LopezSendon J. L., Pais P., Parkhomenko A., Verheugt F. W., Zhu J., Wallentin L.,Investigators A. C. a. Apixaban versus warfarin in patients with atrial fibrillation // NEngl J Med. ‒ 2011. ‒ T. 365, № 11. ‒ C. 981-92.73. Guttmann O. P., Pavlou M., O'Mahony C., Monserrat L., Anastasakis A., Rapezzi C.,Biagini E., Gimeno J. R., Limongelli G., Garcia-Pavia P., McKenna W. J., Omar R. Z.,Elliott P. M., Investigators H. C.
O. Prediction of thrombo-embolic risk in patients withhypertrophic cardiomyopathy (HCM Risk-CVA) // Eur J Heart Fail. ‒ 2015. ‒ T. 17, №8. ‒ C. 837-45.74. Harel Z., Sholzberg M., Shah P. S., Pavenski K., Harel S., Wald R., Bell C. M., PerlJ. Comparisons between novel oral anticoagulants and vitamin K antagonists in patientswith CKD // J Am Soc Nephrol. ‒ 2014. ‒ T. 25, № 3.
‒ C. 431-42.75. Hart R. G., Pearce L. A., Asinger R. W., Herzog C. A. Warfarin in atrial fibrillationpatients with moderate chronic kidney disease // Clin J Am Soc Nephrol. ‒ 2011. ‒ T. 6,№ 11. ‒ C. 2599-604.76. Hart R. G., Pearce L. A., Aguilar M. I. Adjusted-dose warfarin versus aspirin forpreventing stroke in patients with atrial fibrillation // Ann Intern Med. ‒ 2007. ‒ T. 147,№ 8. ‒ C. 590-2.77. Hart R. G., Ingram A. J., Eikelboom J.
W. Which Patients With Atrial Fibrillation andChronic Kidney Disease Should Receive Anticoagulation-And With WhichAnticoagulant? // Can J Cardiol. ‒ 2017. ‒ T. 33, № 2. ‒ C. 211-213.12078. Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapy toprevent stroke in patients who have nonvalvular atrial fibrillation // Ann Intern Med.
‒2007. ‒ T. 146, № 12. ‒ C. 857-67.79. Heidbuchel H., Verhamme P., Alings M., Antz M., Diener H. C., Hacke W., OldgrenJ., Sinnaeve P., Camm A. J., Kirchhof P. Updated European Heart Rhythm AssociationPractical Guide on the use of non-vitamin K antagonist anticoagulants in patients withnon-valvular atrial fibrillation // Europace. ‒ 2015. ‒ T.
17, № 10. ‒ C. 1467-507.80. Hemmelgarn B. R., Zhang J., Manns B. J., Tonelli M., Larsen E., Ghali W. A.,Southern D. A., McLaughlin K., Mortis G., Culleton B. F. Progression of kidneydysfunction in the community-dwelling elderly // Kidney Int. ‒ 2006. ‒ T. 69, № 12. ‒ C.2155-61.81. Hijazi Z., Hohnloser S. H., Oldgren J., Andersson U., Connolly S. J., Eikelboom J.W., Ezekowitz M. D., Reilly P.
A., Siegbahn A., Yusuf S., Wallentin L. Efficacy andsafety of dabigatran compared with warfarin in relation to baseline renal function inpatients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-termAnticoagulation Therapy) trial analysis // Circulation. ‒ 2014. ‒ T. 129, № 9. ‒ C. 96170.82. Hijazi Z., Hohnloser S. H., Andersson U., Alexander J. H., Hanna M., Keltai M.,Parkhomenko A., López-Sendón J.
L., Lopes R. D., Siegbahn A., Granger C. B.,Wallentin L. Efficacy and Safety of Apixaban Compared With Warfarin in Patients WithAtrial Fibrillation in Relation to Renal Function Over Time: Insights From theARISTOTLE Randomized Clinical Trial // JAMA Cardiol. ‒ 2016. ‒ T. 1, № 4. ‒ C. 45160.83. Hobbs F. D., Fitzmaurice D. A., Mant J., Murray E., Jowett S., Bryan S., Raftery J.,Davies M., Lip G. A randomised controlled trial and cost-effectiveness study ofsystematic screening (targeted and total population screening) versus routine practice forthe detection of atrial fibrillation in people aged 65 and over.
The SAFE study // HealthTechnol Assess. ‒ 2005. ‒ T. 9, № 40. ‒ C. iii-iv, ix-x, 1-74.12184. Hohnloser S. H., Hijazi Z., Thomas L., Alexander J. H., Amerena J., Hanna M., KeltaiM., Lanas F., Lopes R. D., Lopez-Sendon J., Granger C. B., Wallentin L. Efficacy ofapixaban when compared with warfarin in relation to renal function in patients with atrialfibrillation: insights from the ARISTOTLE trial // Eur Heart J. ‒ 2012. ‒ T.
33, № 22. ‒C. 2821-30.85. Hylek E. M., Held C., Alexander J. H., Lopes R. D., De Caterina R., Wojdyla D. M.,Huber K., Jansky P., Steg P. G., Hanna M., Thomas L., Wallentin L., Granger C. B. Majorbleeding in patients with atrial fibrillation receiving apixaban or warfarin: TheARISTOTLE Trial (Apixaban for Reduction in Stroke and Other ThromboembolicEvents in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes // J AmColl Cardiol. ‒ 2014. ‒ T.
63, № 20. ‒ C. 2141-2147.86. James M. T., Hemmelgarn B. R., Tonelli M. Early recognition and prevention ofchronic kidney disease // Lancet. ‒ 2010. ‒ T. 375, № 9722. ‒ C. 1296-309.87. January C. T., Wann L. S., Alpert J. S., Calkins H., Cigarroa J. E., Cleveland J. C.,Conti J. B., Ellinor P. T., Ezekowitz M.
D., Field M. E., Murray K. T., Sacco R. L.,Stevenson W. G., Tchou P. J., Tracy C. M., Yancy C. W., Guidelines A. C. o. C. A. H.A. T. F. o. P. 2014 AHA/ACC/HRS guideline for the management of patients with atrialfibrillation: a report of the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines and the Heart Rhythm Society // J Am Coll Cardiol. ‒2014. ‒ T. 64, № 21. ‒ C. e1-76.88.
Jørgensen H. S., Nakayama H., Reith J., Raaschou H. O., Olsen T. S. Acute strokewith atrial fibrillation. The Copenhagen Stroke Study // Stroke. ‒ 1996. ‒ T. 27, № 10. ‒C. 1765-9.89. Khadzhynov D., Wagner F., Formella S., Wiegert E., Moschetti V., Slowinski T.,Neumayer H. H., Liesenfeld K. H., Lehr T., Härtter S., Friedman J., Peters H., ClemensA. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study inpatients with end-stage renal disease // Thromb Haemost.
‒ 2013. ‒ T. 109, № 4. ‒ C.596-605.12290. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO2012 Clinical Practice Guideline for the Evaluation and Management of Chronic KidneyDisease // Kidney inter., Suppl. ‒ 2013. ‒ T. 3. ‒ C. 1 - 150.91. Kimachi M., Furukawa T. A., Kimachi K., Goto Y., Fukuma S., Fukuhara S. Directoral anticoagulants versus warfarin for preventing stroke and systemic embolic eventsamong atrial fibrillation patients with chronic kidney disease // Cochrane Database SystRev. ‒ 2017.
‒ T. 11. ‒ C. CD011373.92. Kimura K., Minematsu K., Yamaguchi T., (J-MUSIC) J. M. S. I. C. Atrial fibrillationas a predictive factor for severe stroke and early death in 15,831 patients with acuteischaemic stroke // J Neurol Neurosurg Psychiatry. ‒ 2005. ‒ T. 76, № 5. ‒ C. 679-83.93. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M.,Diener H.
C., Heidbuchel H., Hendriks J., Hindricks G., Manolis A. S., Oldgren J.,Popescu B. A., Schotten U., Van Putte B., Vardas P., Agewall S., Camm J., BaronEsquivias G., Budts W., Carerj S., Casselman F., Coca A., De Caterina R., Deftereos S.,Dobrev D., Ferro J. M., Filippatos G., Fitzsimons D., Gorenek B., Guenoun M.,Hohnloser S. H., Kolh P., Lip G. Y., Manolis A., McMurray J., Ponikowski P., RosenhekR., Ruschitzka F., Savelieva I., Sharma S., Suwalski P., Tamargo J. L., Taylor C. J., VanGelder I. C., Voors A. A., Windecker S., Zamorano J. L., Zeppenfeld K.
2016 ESCGuidelines for the management of atrial fibrillation developed in collaboration withEACTS // Europace. ‒ 2016. ‒ T. 18, № 11. ‒ C. 1609-1678.94. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M.,Diener H. C., Heidbuchel H., Hendriks J., Hindricks G., Manolis A. S., Oldgren J.,Popescu B. A., Schotten U., Van Putte B., Vardas P., Agewall S., Camm J., BaronEsquivias G., Budts W., Carerj S., Casselman F., Coca A., De Caterina R., Deftereos S.,Dobrev D., Ferro J. M., Filippatos G., Fitzsimons D., Gorenek B., Guenoun M.,Hohnloser S. H., Kolh P., Lip G.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
